Notice2024-28196
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Customer Experience Hub
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 2, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 231 (Monday, December 2, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 231 (Monday, December 2, 2024)]
[Notices]
[Pages 95237-95238]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-28196]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Customer Experience Hub
Notice is hereby given that, on October 1, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), The Customer Experience Hub
(``CX Hub'') has filed written notifications simultaneously with the
Attorney General and the
[[Page 95238]]
Federal Trade Commission disclosing changes in its membership. The
notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances.
Specifically, Alethium Technologies, Inc., West Hollywood, CA;
Alliance for Cancer Gene Therapy, Inc., Stamford, CT; Aret[eacute]
Associates, Northridge, CA; Arsenal Medical, Inc., Waltham, MA; ASC
Biosciences, Inc., Scottsdale, AZ; Association of University Research
Parks Bio Health Caucus, College Park, MD; Barrow Wise Consulting LLC,
Rockville, MD; Baylor College of Medicine, Houston, TX; Bio-Tech
Pharmacal, Inc., Fayetteville, AR; BLEN, Inc., Washington, DC; Boise
State University, Boise, ID; Caelum Diagnostic Solutions, Inc., Marina
Del Rey, CA; Care+ Ventures LLC dba Naveon, Baton Rouge, LA; Clinical
Data Interchange Standards Consortium, Inc., Austin, TX;
CommunicateHealth, Inc., Rockville, MD; Community Health Design Corps
LLC, Nashua, NH; Curavit Clinical Research Corp., Scarsdale, NY; Darena
Solutions LLC, Chesterfield, MO; Eggschain, Inc., Austin, TX; Evernorth
Health Services, Morris Plains, NJ; Exagen, Inc., Vista, CA; Femovate
by Guidea, Austin, TX; FemTechnology, Inc., Middletown, DE; Florida
State University, Tallahassee, FL; Gigantest, Inc., Baltimore, MD; Good
Days, Frisco, TX; Health Evolve Technologies LLC, Columbia, SC; Health
Tech Alley, Inc., Columbia, MD; Icarus Therapeutics, San Diego, CA; ICF
Incorporated LLC, Reston, VA; Ignite Health, Houston, TX; Imaginostics,
Orlando, FL; Imago Rehab, Inc., Lowell, MA; Immersion, Phoenix, AZ;
InsiteOne LLC, Wallingford, CT; InvivoSciences, Inc., Madison, WI;
JEEVA Clinical Trials, Inc., Manassas, VA; Kaiser Foundation Research
Institute, Oakland, CA; Langrand and Company LLC, Houston, TX; Leva
LLC, Westwood Hills, KS; LexisNexis Risk Solutions, Inc., Alpharetta,
GA; MD Health Pathways, Dallas, TX; MedeAnalytics, Inc., Richardson,
TX; MediPro Direct, Salt Lake City, UT; MentalHappy, Inc., San
Francisco, CA; Metis Foundation, San Antonio, TX; Mike A. Myers Stroke
Center, Dallas, TX; Minerva Medical Consulting LLC dba Menrva, Dallas,
TX; MyHealth.Us, New York, NY; NanoMood Technologies LLC, La Jolla, CA;
Nave Security, Charlotte, NC; OmniNano Pharmaceuticals LLC, Houston,
TX; OncoSenX, Seattle, WA; PatientLink Enterprises, Inc., Oklahoma
City, OK; Perimeter Medical Imaging Corp., Dallas, TX; Radyus Research,
Inc., Atlanta, GA; Regents of the University of Michigan, Ann Arbor,
MI; Regents of the University of Minnesota, Minneapolis, MN;
Saltusbiotech, Pleasanton, CA; Sama Therapeutics, Inc., Cambridge, MA;
Sky Solutions LLC, Herndon, VA; Smart Information Flow Technologies
LLC, Minneapolis, MN; Society of Physician Entrepreneurs, South
Norwalk, CT; Solving MS, Edmonds, WA; Southern Methodist University,
Dallas, TX; Syncoro Health LLC, Northville, MI; The Innovation
Foundation at Oklahoma State University, Inc., Stillwater, OK; The Ohio
State University, Columbus, OH; Third Pole, Inc., Waltham, MA; Tranquil
Clinical Research, Webster, TX; Triton Systems, Inc., Chelmsford, MA;
University of Connecticut, Storrs, CT; University of Maryland,
Baltimore, Baltimore, MD; University of South Florida Institute of
Applied Engineering, Inc., Tampa, FL; Virginia Commonwealth University
Massey Comprehensive Cancer Center, Richmond, VA; Visilant, Baltimore,
MD; and XR 2 LEAD LLC, Dumfries, VA have been added as parties to this
venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and the CX Hub intends to file
additional written notifications disclosing all changes in membership.
On January 11, 2024, the CX Hub filed its original notification
pursuant to section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to section 6(b) of
the Act on April 16, 2024 (89 FR 26929).
The last notification was filed with the Department on July 3,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on September 26, 2024 (89 FR 78902).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-28196 Filed 11-29-24; 8:45 am]
BILLING CODE 4410-11-P
</pre></body>
</html>Indexed from Federal Register on December 2, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.